Atlas Trials

Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer

Clinical trial NCT02688608 · COMPLETED

Trial details

NCT number
NCT02688608
Sponsor
Saad A Khan
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Anaplastic Thyroid Cancer
Start date
2016-10-01
Primary completion
2020-10-01
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.